[go: up one dir, main page]

WO1998008517A3 - Composition pharmaceutique contenant une substance favorisant l'osteogenese et un polyethylene glycol - Google Patents

Composition pharmaceutique contenant une substance favorisant l'osteogenese et un polyethylene glycol Download PDF

Info

Publication number
WO1998008517A3
WO1998008517A3 PCT/JP1997/002941 JP9702941W WO9808517A3 WO 1998008517 A3 WO1998008517 A3 WO 1998008517A3 JP 9702941 W JP9702941 W JP 9702941W WO 9808517 A3 WO9808517 A3 WO 9808517A3
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical composition
polyethylene glycol
promoting substance
composition containing
osteogenesis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP1997/002941
Other languages
English (en)
Other versions
WO1998008517A2 (fr
Inventor
Tetsuo Hoshino
Kazuhiro Saito
Susumu Iwasa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Priority to DE69716469T priority Critical patent/DE69716469T2/de
Priority to AT97935871T priority patent/ATE226078T1/de
Priority to AU38689/97A priority patent/AU3868997A/en
Priority to EP97935871A priority patent/EP0949927B1/fr
Priority to CA002264131A priority patent/CA2264131A1/fr
Publication of WO1998008517A2 publication Critical patent/WO1998008517A2/fr
Publication of WO1998008517A3 publication Critical patent/WO1998008517A3/fr
Priority to US09/246,851 priority patent/US6190695B1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La présente invention concerne une composition pharmaceutique comprenant une substance non peptidique favorisant l'ostéogenèse et un polyéthylène glycol ou l'un de ses dérivés. Cette composition convient particulièrement comme agent de prévention ou de traitement de différentes affections osseuses (par exemple l'ostéoporose) en raison des niveaux élevés d'absorbabilité et de stabilité per os du principe actif.
PCT/JP1997/002941 1919-04-09 1997-08-25 Composition pharmaceutique contenant une substance favorisant l'osteogenese et un polyethylene glycol Ceased WO1998008517A2 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
DE69716469T DE69716469T2 (de) 1996-08-26 1997-08-25 Pharmazeutische zusammensetzung enthaltend ein osteogenese foerderndes mittel und ein polyethylen-glycol
AT97935871T ATE226078T1 (de) 1996-08-26 1997-08-25 Pharmazeutische zusammensetzung enthaltend ein osteogenese foerderndes mittel und ein polyethylen-glycol
AU38689/97A AU3868997A (en) 1996-08-26 1997-08-25 Pharmaceutical composition containing osteogenesis-promoting substance and a polyethylene glycol
EP97935871A EP0949927B1 (fr) 1996-08-26 1997-08-25 Composition pharmaceutique contenant une substance favorisant l'osteogenese et un polyethylene glycol
CA002264131A CA2264131A1 (fr) 1996-08-26 1997-08-25 Composition pharmaceutique contenant une substance favorisant l'osteogenese
US09/246,851 US6190695B1 (en) 1919-04-09 1999-02-09 Pharmaceutical composition containing osteogenesis-promoting substance

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP8/223443 1996-08-26
JP22344396 1996-08-26
JP9040897 1997-04-09
JP9/90408 1997-04-09

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US09/246,851 Continuation US6190695B1 (en) 1919-04-09 1999-02-09 Pharmaceutical composition containing osteogenesis-promoting substance

Publications (2)

Publication Number Publication Date
WO1998008517A2 WO1998008517A2 (fr) 1998-03-05
WO1998008517A3 true WO1998008517A3 (fr) 1998-05-07

Family

ID=26431895

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP1997/002941 Ceased WO1998008517A2 (fr) 1919-04-09 1997-08-25 Composition pharmaceutique contenant une substance favorisant l'osteogenese et un polyethylene glycol

Country Status (9)

Country Link
US (1) US6190695B1 (fr)
EP (1) EP0949927B1 (fr)
AT (1) ATE226078T1 (fr)
AU (1) AU3868997A (fr)
CA (1) CA2264131A1 (fr)
DE (1) DE69716469T2 (fr)
ES (1) ES2181017T3 (fr)
ID (1) ID18079A (fr)
WO (1) WO1998008517A2 (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IS4518A (is) * 1997-07-09 1999-01-10 Lyfjathroun Hf, The Icelandic Bio Pharmaceutical Group Nýtt lyfjaform fyrir bóluefni
CA2334815A1 (fr) * 1998-06-15 1999-12-23 Haruhiko Makino Composition traitant une maladie du cartilage
WO2000008018A1 (fr) 1998-08-07 2000-02-17 Takeda Chemical Industries, Ltd. Derives de benzothiepine, leur procede de preparation et leurs utilisations
WO2000009100A2 (fr) * 1998-08-12 2000-02-24 Takeda Chemical Industries, Ltd. Renforçateur du facteur d'induction de la differenciation cellulaire
AU6318900A (en) * 1999-08-05 2001-03-05 Takeda Chemical Industries Ltd. Pastes with the sustained release of osteogenesis promoter
EP1293197A1 (fr) * 2000-06-23 2003-03-19 Takeda Chemical Industries, Ltd. Procede de production de medicaments contenant des phospholipides
US7748388B2 (en) * 2001-01-19 2010-07-06 Hironori Yamamoto Endoscopic injectable preparation
US6855332B2 (en) * 2002-07-03 2005-02-15 Lyfjathroun Hf. Absorption promoting agent
US8158685B2 (en) * 2004-07-02 2012-04-17 Gregory Gene Steiner Method for bone growth
SI3095447T1 (sl) 2006-02-03 2022-02-28 Opko Renal, Llc Zdravljenje pomanjkanja vitamina D s 25-hidroksivitaminom D2 in 25-hidroksivitaminom D3
ES2670029T3 (es) 2006-06-21 2018-05-29 Opko Ireland Global Holdings, Ltd. Terapia usando agente de repleción de la vitamina D y agente de reemplazo de la hormona de la vitamina D
JP5647516B2 (ja) * 2007-04-25 2014-12-24 シトクロマ インコーポレイテッド ビタミンｄ療法のための方法および化合物
DK2148661T3 (da) 2007-04-25 2013-03-25 Cytochroma Inc Orale præparater med kontrolleret afgivelse omfattende vitamin D-forbindelse og voksagtig bærer
DK3225243T3 (da) 2007-04-25 2025-09-29 Opko Renal Llc Metode til sikker og effektiv behandling og forebyggelse af sekundær hyperparatyreoidisme ved kronisk nyresygdom
EP2148684B1 (fr) * 2007-04-25 2013-01-16 Cytochroma Inc. Procédé de traitement d'une insuffisance et d'une carence en vitamine d
ES2593356T3 (es) 2008-04-02 2016-12-07 Opko Ireland Global Holdings, Ltd. Métodos, composiciones, usos y kits útiles para la deficiencia de la vitamina D y trastornos relacionados
CA2797537C (fr) 2010-03-29 2021-11-23 Cytochroma Inc. Utilisation du compose de 25-hydroxyvitamine d pour la reduction des niveaux de la parathyroide
KR101847947B1 (ko) 2013-03-15 2018-05-28 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 안정화되고 변형된 비타민 ｄ 방출 제형
US10220047B2 (en) 2014-08-07 2019-03-05 Opko Ireland Global Holdings, Ltd. Adjunctive therapy with 25-hydroxyvitamin D and articles therefor
KR20230054752A (ko) 2016-03-28 2023-04-25 옵코 아일랜드 글로벌 홀딩스 리미티드 비타민 d 치료 방법

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0328806A2 (fr) * 1988-02-16 1989-08-23 Paco Pharmaceutical Services Système d'administration transdermique d'oestradiol
EP0460488A1 (fr) * 1990-05-30 1991-12-11 Takeda Chemical Industries, Ltd. Composés hétérocycliques contenant du soufre
WO1994023740A1 (fr) * 1993-04-22 1994-10-27 Celtrix Pharmaceuticals, Inc. Conjugues du facteur de croissance et d'inhibiteur de la resorption osseuse
JPH06321790A (ja) * 1993-05-12 1994-11-22 Hoyu Co Ltd 速崩壊性生薬製剤
EP0719782A1 (fr) * 1994-12-28 1996-07-03 Takeda Chemical Industries, Ltd. Dérivé de benzotiépine optiquement actif, sa préparation et son utilisation
WO1996039134A1 (fr) * 1995-06-05 1996-12-12 Takeda Chemical Industries, Ltd. Composition pharmaceutique favorisant l'osteogenese

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ231939A (en) 1988-12-28 1991-07-26 Takeda Chemical Industries Ltd Benzothiopyran derivatives and medicaments

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0328806A2 (fr) * 1988-02-16 1989-08-23 Paco Pharmaceutical Services Système d'administration transdermique d'oestradiol
EP0460488A1 (fr) * 1990-05-30 1991-12-11 Takeda Chemical Industries, Ltd. Composés hétérocycliques contenant du soufre
WO1994023740A1 (fr) * 1993-04-22 1994-10-27 Celtrix Pharmaceuticals, Inc. Conjugues du facteur de croissance et d'inhibiteur de la resorption osseuse
JPH06321790A (ja) * 1993-05-12 1994-11-22 Hoyu Co Ltd 速崩壊性生薬製剤
EP0719782A1 (fr) * 1994-12-28 1996-07-03 Takeda Chemical Industries, Ltd. Dérivé de benzotiépine optiquement actif, sa préparation et son utilisation
WO1996039134A1 (fr) * 1995-06-05 1996-12-12 Takeda Chemical Industries, Ltd. Composition pharmaceutique favorisant l'osteogenese

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Section Ch Week 9506, Derwent World Patents Index; Class A96, AN 95-041194, XP002058310, "Rapidly disintegrating crude drug preparation - containing PEG, and carboxy-methyl derivatives of cellulose or starch" *
H. P. FIEDLER: "LEXIKON DER HILFSTOFFE FUR PHARMAZIE, KOSMETIK UND ANGRENZENDE GEBIETE", 1996, EDITIO CANTOR VERLAG FÜR MEDIZIN UND NATURWISSENSCHAFTEN, AULENDORF, XP002058309 *
MIYAMOTO S ET AL: "POLYACTIC ACID-POLYETHYLENE GLYCOL BLOCK COPOLYMER A NEW BIODEGRADABLE SYNTHETIC CARRIER FOR BONE MORPHOGENETIC PROTEIN", CLINICAL ORTHOPEDICS, no. 294, September 1993 (1993-09-01), pages 333 - 343, XP000600897 *

Also Published As

Publication number Publication date
EP0949927B1 (fr) 2002-10-16
US6190695B1 (en) 2001-02-20
ID18079A (id) 1998-02-26
CA2264131A1 (fr) 1998-03-05
DE69716469T2 (de) 2003-02-20
DE69716469D1 (de) 2002-11-21
ATE226078T1 (de) 2002-11-15
ES2181017T3 (es) 2003-02-16
EP0949927A2 (fr) 1999-10-20
WO1998008517A2 (fr) 1998-03-05
AU3868997A (en) 1998-03-19

Similar Documents

Publication Publication Date Title
WO1998008517A3 (fr) Composition pharmaceutique contenant une substance favorisant l'osteogenese et un polyethylene glycol
AU2001232337A1 (en) Pharmaceutical composition, reagent and method for intracerebral delivery of pharmaceutically active ingredient or labeling substance
HUP0001170A3 (en) Pharmaceutical compositions containing benzimidazole-2-carbamate derivatives as active ingredients for the treatment of viral infections and cancer
MY118151A (en) Pharmaceutical formulations containing voriconazole.
WO2003002136A3 (fr) Formulation stable de glp-1 modifie
YU59192A (sh) Formulacija aerosola koje ne sadrže hlorofluorougljenična jedinjenja
EP1114816A4 (fr) DERIVES E DE PHENYL-PROSTAGLANDINE A SUBSTITUTION-$g(V) ET MEDICAMENTS LES CONTENANT COMME INGREDIENT ACTIF
ES2175413T5 (es) Formulaciones de aerosol
CA2366679A1 (fr) Composition pharmaceutique orale stabilisee contenant de l'iodure et de l'iodate et procede associe
EP0679393A3 (fr) Composition pharmaceutique pour le traitement de l'ostéoporose contenant du xanthohumol
GR3007107T3 (fr)
IL112627A0 (en) Diketopiperazines, their preparation and pharmaceutical or veterinary compositions containing them
IL145012A0 (en) Fluorine substituted triarylmethane derivatives and pharmaceutical compositions containing the same
IL143577A0 (en) Piperazine derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same
HUP9901326A3 (en) Benzopyran derivatives having leukotriene-antagonistic action, pharmaceutical compositions containing these compounds, process for the preparation and use of these compounds and compositions
HUP0100024A3 (en) Pharmaceutical compositions for treating alzheimer's disease containing carvedilol as active ingredient
HUP0102369A3 (en) Amino acid derivatives and drugs containing the same as the active ingredient
AU5892399A (en) 1, 2, 4-triazole-3-thione compounds
HUP0000960A3 (en) Spray-dried paroxetine hydrochloride, process for it's preparation,use of the compound and pharmaceutical compositions containing the same
CA2376894A1 (fr) Composition pharmaceutique comprenant une proteine et une ectoine
HUP0303636A3 (en) Dihydronaphthalenederivative compounds and pharmaceutical compositions containing them as active ingredient
AU2670600A (en) Pharmaceutical composition containing desoxypeganine for the treatment of nicotine dependence
HUP9802897A3 (en) Optically active pyridyl-4h-1,2,4-oxadiazine derivatives, the use thereof in the treatment of vascular diseases and pharmaceutical composition containing the compound as active ingredient
HUP9901680A3 (en) Use of piperazin-, piperidin- or hexahidropiridazin derivatives for the preparation of pharmaceutical compositions, new piperazin derivatives and pharmaceutical compositions containing these compounds
EP1084710A4 (fr) Medicaments contre la sterilite masculine

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AU AZ BA BB BG BR BY CA CN CU CZ EE GE HU IL IS KG KR KZ LC LK LR LT LV MD MG MK MN MX NO NZ PL RO RU SG SI SK SL TJ TM TR TT UA US UZ VN YU AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AU AZ BA BB BG BR BY CA CN CU CZ EE GE HU IL IS KG KR KZ LC LK LR LT LV MD MG MK MN MX NO NZ PL RO RU SG SI SK SL TJ TM TR TT UA US UZ VN YU AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1997935871

Country of ref document: EP

Ref document number: 09246851

Country of ref document: US

ENP Entry into the national phase

Ref document number: 2264131

Country of ref document: CA

Kind code of ref document: A

Ref document number: 2264131

Country of ref document: CA

WWP Wipo information: published in national office

Ref document number: 1997935871

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1997935871

Country of ref document: EP